D.E. Shaw & Co’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-113,848
| Closed | -$665K | – | 5144 |
|
|
2022
Q4 | $665K | Buy |
+113,848
| New | +$599K | ﹤0.01% | 3703 |
|
|
2022
Q3 | – | Sell |
-25,901
| Closed | -$109K | – | 5709 |
|
|
2022
Q2 | $109K | Sell |
25,901
-6,646
| -20% | -$26.3K | ﹤0.01% | 4710 |
|
|
2022
Q1 | $110K | Sell |
32,547
-12,772
| -28% | -$40.5K | ﹤0.01% | 4984 |
|
|
2021
Q4 | $143K | Buy |
45,319
+18,296
| +68% | +$60.9K | ﹤0.01% | 4982 |
|
|
2021
Q3 | $88K | Sell |
27,023
-4,704
| -15% | -$16.5K | ﹤0.01% | 4739 |
|
|
2021
Q2 | $134K | Sell |
31,727
-37,102
| -54% | -$157K | ﹤0.01% | 4515 |
|
|
2021
Q1 | $344K | Buy |
68,829
+10,756
| +19% | +$86.9K | ﹤0.01% | 3654 |
|
|
2020
Q4 | $734K | Buy |
58,073
+2,004
| +4% | +$22.8K | ﹤0.01% | 3208 |
|
|
2020
Q3 | $551K | Buy |
56,069
+23,478
| +72% | +$231K | ﹤0.01% | 3181 |
|
|
2020
Q2 | $324K | Buy |
32,591
+4,659
| +17% | +$44.7K | ﹤0.01% | 3593 |
|
|
2020
Q1 | $247K | Sell |
27,932
-12,499
| -31% | -$123K | ﹤0.01% | 3565 |
|
|
2019
Q4 | $373K | Buy |
40,431
+354
| +0.9% | +$2.51K | ﹤0.01% | 3539 |
|
|
2019
Q3 | $236K | Sell |
40,077
-10,892
| -21% | -$116K | ﹤0.01% | 3566 |
|
|
2019
Q2 | $612K | Buy |
50,969
+7,812
| +18% | +$84K | ﹤0.01% | 2972 |
|
|
2019
Q1 | $521K | Sell |
43,157
-915
| -2% | -$13.5K | ﹤0.01% | 2988 |
|
|
2018
Q4 | $553K | Sell |
44,072
-22,569
| -34% | -$312K | ﹤0.01% | 3040 |
|
|
2018
Q3 | $989K | Buy |
66,641
+7,578
| +13% | +$119K | ﹤0.01% | 2710 |
|
|
2018
Q2 | $994K | Buy |
59,063
+12,196
| +26% | +$237K | ﹤0.01% | 2706 |
|
|
2018
Q1 | $1.07M | Sell |
46,867
-56,550
| -55% | -$1.26M | ﹤0.01% | 2445 |
|
|
2017
Q4 | $2.67M | Sell |
103,417
-198,419
| -66% | -$4M | ﹤0.01% | 1918 |
|
|
2017
Q3 | $4.45M | Sell |
301,836
-13,893
| -4% | -$202K | 0.01% | 1463 |
|
|
2017
Q2 | $4.4M | Buy |
315,729
+22,426
| +8% | +$331K | 0.01% | 1437 |
|
|
2017
Q1 | $5M | Buy |
293,303
+235,015
| +403% | +$2.82M | 0.01% | 1297 |
|
|
2016
Q4 | $600K | Buy |
58,288
+17,785
| +44% | +$163K | ﹤0.01% | 2746 |
|
|
2016
Q3 | $409K | Buy |
40,503
+15,692
| +63% | +$171K | ﹤0.01% | 2894 |
|
|
2016
Q2 | $279K | Buy |
+24,811
| New | +$316K | ﹤0.01% | 3058 |
|
D.E. Shaw & Co's CNCE Position: Q1 2023 in Review
D.E. Shaw & Co sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 113,848 shares — an estimated $665K sold.
D.E. Shaw & Co first reported a position in CNCE in Q2 2016 and held it in 26 quarters. The position peaked at $5M in Q1 2017. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- D.E. Shaw & Co reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- D.E. Shaw & Co sold 113,848 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $665K.
- D.E. Shaw & Co first reported a position in Concert Pharmaceuticals, Inc. in Q2 2016 and held it in 26 quarters.
- D.E. Shaw & Co's Concert Pharmaceuticals, Inc. position peaked at $5M in Q1 2017.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.